计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| O413864-5mg |
5mg |
期货 ![]() |
| |
| O413864-10mg |
10mg |
现货 ![]() |
| |
| O413864-25mg |
25mg |
期货 ![]() |
| |
| O413864-50mg |
50mg |
现货 ![]() |
| |
| O413864-100mg |
100mg |
现货 ![]() |
|
| 别名 | 奥纳塔塞蒂布 (CC 223) |
|---|---|
| 英文别名 | AKOS030526335 | Pyrazino(2,3-b)pyrazin-2(1H)-one, 3,4-dihydro-7-(6-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-(trans-4-methoxycyclohexyl)- | 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(4-methoxycyclohexyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one | CHEBI:169 |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Onatasertib (CC 223) |
| 生化机理 | 奥纳他替(Onatasertib,CC 223)是一种强效、选择性和口服生物可用性 mTOR 抑制剂,其 IC50 值为 16 nM,比相关的 PI3K-α 的选择性高 200 倍以上。1/2阶段。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 集落刺激因子 1 受体抑制剂;FMS 相关受体酪氨酸激酶 4 抑制剂;雷帕霉素激酶机制靶点抑制剂 |
| 产品介绍 |
Information Onatasertib (CC 223) Onatasertib (CC 223) is a potent, selective, and orally bioavailable mTOR inhibitor with IC50 of 16 nM, >200-fold selectivity over the related PI3K-α. Phase 1/2. Targets mTOR (Cell-free assay); cFMS (Cell-free assay); FLT4 (Cell-free assay); DNA-PK (Cell-free assay) 16 nM; 28 nM; 651 nM; 840 nM In vitro In a panel of cell lines, CC-223 inhibits both mTORC1 (S6RP and 4EBP1) and mTORC2 [AKT(S473)] markers with IC50 ranges of 27 to 184 nM for pS6RP, 120 to 1,050 nM for p4EBP1 and 11 to 150 nM for pAKT(S473), respectively. CC-223 also inhibits cell growth and induces apoptosis across a number of cancer cell lines. In vivo In PC-3 tumor-bearing mice, CC-223 (25 mg/kg, p.o.) inhibits both mTORC1 and mTORC2. CC-223 (25 mg/kg, p.o.) also results in tumor growth inhibition by 47% to 95% in xenograft models of prostate, glioma, breast, lung, and colon. Cell Research(from reference) Cell lines:PC-3, CAL-51, A549,T47D,NCI-H460, HepG2, AU565, Hep3B, HCC, U87MG, HCT116, MDA-MB-231, and NCI-H23 cells Concentrations:~ 10 μM Incubation Time:72 h |
| 纯度 | ≥99% |
| ALogP | 1.66 |
|---|---|
| hba_count | 5 |
| HBD Count | 1 |
| Rotatable Bond | 4 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504771671 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(4-methoxycyclohexyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one |
| INCHI | 1S/C21H27N5O3/c1-21(2,28)17-9-4-13(10-22-17)16-11-23-19-20(25-16)26(18(27)12-24-19)14-5-7-15(29-3)8-6-14/h4,9-11,14-15,28H,5-8,12H2,1-3H3,(H,23,24) |
| InChi Key | UFKLYTOEMRFKAD-UHFFFAOYSA-N |
| Smiles | CC(C)(C1=NC=C(C=C1)C2=CN=C3C(=N2)N(C(=O)CN3)C4CCC(CC4)OC)O |
| Isomeric SMILES | CC(C)(C1=NC=C(C=C1)C2=CN=C3C(=N2)N(C(=O)CN3)C4CCC(CC4)OC)O |
| 关联CAS | 1228013-30-6 |
| MeSH Entry Terms | 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(4-methoxycyclohexyl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one;CC-223;CC0482223 |
| 分子量 | 397.47 |
| Reaxy-Rn | 27223668 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=27223668&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 79 mg/mL (198.75 mM); Ethanol: 79 mg/mL (198.75 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 79 |
| DMSO(mM) Max Solubility | 198.7571389 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 397.500 g/mol |
| XLogP3 | 1.100 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 397.211 Da |
| 单同位素质量Monoisotopic Mass | 397.211 Da |
| 拓扑极表面积Topological Polar Surface Area | 100.000 Ų |
| 重原子数Heavy Atom Count | 29 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 581.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Mortensen DS, Perrin-Ninkovic SM, Harris R, Lee BG, Shevlin G, Hickman M, Khambatta G, Bisonette RR, Fultz KE, Sankar S. (2011) Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.. Bioorg Med Chem Lett, 21 (22): (6793-9). [PMID:21978683] |
| 2. Mortensen DS, Perrin-Ninkovic SM, Shevlin G, Zhao J, Packard G, Bahmanyar S, Correa M, Elsner J, Harris R, Lee BG et al.. (2015) Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.. J Med Chem, 58 (13): (5323-33). [PMID:26083478] |